Clinical Trials Logo
  1. Home
  2. Lysosomal Storage Diseases
  3. NCT03853876

A Natural History Study of Aspartylglucosaminuria — AGU  

Lysosomal Storage Diseases Clinical Trial

Official title:
A Natural History Study of Aspartylglucosaminuria

Clinical Trial Summary

Aspartylglucosaminuria (AGU) is a rare neurodegenerative lysosomal storage disease (LSD) characterized by developmental delay, psychomotor regression, worsening intellectual disability, gait disturbance and, ultimately, premature death, and has no available treatments. The purpose of this study is to investigate the clinical characteristics and natural clinical progression of symptoms in individuals with AGU. This natural history study is important to better understand disease course to be able to determine clinically meaningful outcome measures for use in future clinical trials.

Clinical Trial Description

Lysosomal storage disorders (LSDs) are a group of inherited metabolic diseases caused by a genetic mutation resulting in deficiency or absence of a critical enzyme, leading to the accumulation of toxic deposits in cells across multiple organ systems. Aspartylglucosaminuria (AGU) is a rare, neurodegenerative, LSD, caused by a deficiency of the aspartylglucosaminidase (AGA) enzyme, which leads to toxic accumulation of aspartylglucosamine and subsequent cellular dysfunction. AGU has been most commonly reported in people of Finnish and Nordic descent, but is present across ethnicities and is typically misdiagnosed or undiagnosed. Aspartylglucosaminuria (AGU) is characterized by developmental delay and intellectual disability that worsens with age. Early disease is characterized by increased frequency of bacterial ear infections, recurrent ear tube placement, intestinal dysfunction, disruptive sleep patterns, skeletal abnormalities, and gait disturbances, among others. Individuals progressively lose motor and cognitive skills, develop behavioral/emotional lability and their risk of seizures increases with age. People with AGU have a shortened life span. No prospective natural history study for AGU has been reported. This study aims to prospectively investigate the natural history of AGU, and concurrently to identify potential outcome measures that could be used in future clinical trials. No investigational product will be provided in the study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03853876
Study type Observational
Source Neurogene Inc.
Contact
Status Terminated
Phase
Start date April 18, 2019
Completion date March 17, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT04455230 - A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190 Phase 1/Phase 2
Withdrawn NCT04189601 - Complement Activation in the Lysosomal Storage Disorders
Withdrawn NCT01003912 - Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases Phase 1
Active, not recruiting NCT04093349 - A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE) Phase 1/Phase 2
Completed NCT02363153 - Diet and Exercise in Pompe Disease N/A
Terminated NCT00215527 - Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I Phase 1
Terminated NCT01963650 - Natural History Study of Children With Metachromatic Leukodystrophy
Recruiting NCT04393701 - A Pilot Study for Systematic Neonatal Screening for Lysosomal Storage Diseases Using Tandem Mass Spectrometry N/A
Suspended NCT04399694 - Identification and Characterization of Novel Non-Coding Variants That Contribute to Genetic Disorders
Active, not recruiting NCT03812042 - Screening of Lysosomal Storage Disorders Diseases in Minority Groups
Completed NCT03893240 - Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease N/A
Active, not recruiting NCT03897361 - Stem Cell Gene Therapy for Cystinosis Phase 1/Phase 2
Terminated NCT04040049 - A Fabry Disease Gene Therapy Study Phase 1/Phase 2
Recruiting NCT03812055 - Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders
Enrolling by invitation NCT04943991 - Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score N/A
Active, not recruiting NCT04283227 - OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD) Phase 3
Recruiting NCT03333200 - Longitudinal Study of Neurodegenerative Disorders
Completed NCT02416661 - Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease
Not yet recruiting NCT06130228 - Nutritional Therapy in Late-onset Pompe Disease Phase 2